Grant: Project Grant
Queen's University (Kingston, Ontario)
$911,116.00
Translating synthetic lethality with common driver events into targeted therapies for high fatality cancers
EF 2021-22
Résumé
Cancer continues to be a leading cause of death for Canadians. Several types of cancer lack effective therapies, especially those that are targeted to the frequently mutated genes that are essential for tumour growth, survival or spread in the body. This project uses genome editing methods to define new genetic susceptibilities in several high risk cancers, including breast, pancreatic and brain cancers. Our team will leverage results of these screens to test new forms of targeted therapy in these cancer models using clinically approved drugs when possible (also called drug repurposing). The impacts of our study include a better understanding of cancer biology, and identification of viable new targeted therapies matched to genes that are frequently mutated in high risk cancers.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
444378
Name
Craig Andrew W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics 2
Projecttitle
Translating synthetic lethality with common driver events into targeted therapies for high fatality cancers
Programtype2
Operating Grants
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$911,116
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cancer; Crispr/Cas9; Driver Mutations; Genome-Wide Screening; Patient-Derived Xenograft Models; Synthetic Lethality; Targeted Therapy; Tumour Xenograft Models
Abstract
Cancer continues to be a leading cause of death for Canadians. Several types of cancer lack effective therapies, especially those that are targeted to the frequently mutated genes that are essential for tumour growth, survival or spread in the body. This project uses genome editing methods to define new genetic susceptibilities in several high risk cancers, including breast, pancreatic and brain cancers. Our team will leverage results of these screens to test new forms of targeted therapy in these cancer models using clinically approved drugs when possible (also called drug repurposing). The impacts of our study include a better understanding of cancer biology, and identification of viable new targeted therapies matched to genes that are frequently mutated in high risk cancers.
Competitiondate
202104
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Craig, Andrew W; Babak, Tomas
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $911,116~ $0~
